Protagonist Therapeutics ( (PTGX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Protagonist Therapeutics’ stock experienced an upward movement following the release of promising Phase 2b results for its drug Icotrokinra. The drug’s efficacy and safety in treating ulcerative colitis have led to an optimistic outlook, prompting analysts to raise the price target. This positive reassessment is backed by the therapeutic potential of Icotrokinra, keeping analysts bullish on the stock.
More about Protagonist Therapeutics
YTD Price Performance: 71.99%
Average Trading Volume: 849,013
Technical Sentiment Signal: Buy
Current Market Cap: $4.06B
For further insights into PTGX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.